High-Touch Wipe Down: Decreasing C. diff Rates in Adults With Cancer
Following a high rate of CDIs, the inpatient medical oncology unit at the University of California, Los Angeles, Santa Monica Medical Center adapted an evidence-based intervention.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
